Purchase Order 75N92025P00214

Award Date 9/12/25
Potential Completion Date 9/11/26
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $95,931.00 firm fixed price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), a civilian agency. The contract is for the purchase of an Illumina MiSeq2 sequencing system and associated components. Illumina, Inc., a for-profit manufacturer of genomic analysis instruments and reagents, is the prime contractor. This contract does not have a set-aside designation. Illumina has provided...
This is a firm fixed-price delivery order awarded by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies. The $48,994.05 contract is for the procurement of an Illumina MiSeq I100 sequencing system and associated reagents and services, to support high-quality DNA sequencing and genomic research at NHLBI. The contract has an ultimate...
This is a firm-fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for a MiSeq support plan. The contract has a ceiling value of $85,029.08 and a period of performance through September 11, 2029. Illumina, a manufacturer of genetic sequencing instruments and reagents, has provided a range of sequencing products and services to support research and diagnostics across various...
This firm fixed-price purchase order contract, awarded by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), provides Illumina, Inc. with a NovaSeq X Plus sequencing system to support genomic research initiatives. The $999,999.00 contract has a completion date of September 19, 2024. Illumina is a leading manufacturer of genetic sequencing and analysis technologies, and has been awarded numerous federal contracts and grants to supply sequencing...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the maintenance of an Illumina MiSeq sequencer used for immunology and inflammation research. The contract has a ceiling value of $16,198.00 and a period of performance through May 26, 2026. Illumina, a leading manufacturer of genetic sequencing and genomic analysis technologies, has been...
This is a firm fixed price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the provision of sequencing services. The contract has a ceiling value of $95,569.54 and does not include any set-aside provisions. Illumina, a manufacturer of genetic analysis instruments and reagents, has previously received prime federal contracts and grants from agencies including the NIH, Centers...
This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis instruments and reagents. The $190,561.89 contract is for Illumina's sequencing services and is not set-aside. Illumina has provided similar sequencing goods and services to support research and diagnostics for various federal...
This is a firm fixed-price delivery order awarded by the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), a civilian federal agency. The $42,511.56 contract is for Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide Illumina sequencing kits and reagents to support next-generation DNA sequencing activities at the NHLBI Sequencing Core Facility. The contract has a performance period ending on...
This is a firm fixed price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract has a ceiling value of $646,396.36 and no set-aside designation. Illumina, a manufacturer of sequencing and array-based genomic analysis solutions, will provide a range of sequencing systems, reagents, and services to support NHLBI's research and diagnostics needs. Illumina has a history of...
This $28,709.96 firm fixed price delivery order was awarded by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the maintenance and support of a NextSeq sequencing instrument to enable DNA sequencing and genomics research for NHLBI principal investigators, fellows, and staff. The award has no set-aside designation. Illumina, a manufacturer of sequencing and genomic analysis instruments and reagents, has...

This is a $15,849.80 firm fixed price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract is for the maintenance of a MiSeq M06580 DNA sequencing instrument and associated services. The contract has a period of performance through September 11, 2026. Illumina, a manufacturer of genomic sequencing technologies, has been awarded multiple federal contracts and grants by the NIH, Centers for Disease Control, Department of Agriculture, Department of Veterans Affairs, and Food and Drug Administration to provide advanced sequencing platforms, reagents, and related services. This contract does not utilize a set-aside designation.

Generated 6/5/25, 10:02 AM